Synaptogenix, Inc., an emerging biopharmaceutical company developing regenerative therapeutics for neurodegenerative disorders, commented on the positive Phase 3 trial results for Lecanemab announced last...
Regeneron Pharmaceuticals, Inc. and Sanofi today announced that a Phase 3 trial assessing the investigational use of Dupixent (dupilumab) in children aged 1 to...
